iProXProteomicsWeijie QinHomo Sapienshttp://www.iprox.org/page/project.html?id=IPX0010789000aunp_dna@126.comNational Center for Protein Science(Beijing)iProXkappaN(23), Xcytrin, Immunomodulatory IMiD, MGd, (methylamino)acetic acid, Neoplasms, postnatal development, Immunomodulating, Degradation, Benign Neoplasm, Immunomodulating Drugs, N-methylaminoacetic acid, SDH, growth and development, Tumor, ONR1, Malignant, Immunomodulatory, IMiDs, kappaN(24), SARD, MeGly, PARq, L-sarcosine, kappaN(25))gadolinium, Drugs, pheromone catabolism, Immunomodulatory IMiDE Drugs, AW108387, Malignancy, PXR, DMGDHL1, 21-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-4, Protein Degradations, Immunomodulatory Agents, Protein Degradation, kappaN(18), Neoplasias, methylaminoacetic acid, malignant neoplasm, 18-benzodiazacycloeicosine-5, SAR supergroup, Structure-Activity Relationships, Malignancies, Relationship, gadolinium texaphyrin, Immunomodulatory Drugs, Cancer, Tumors, PAR, Degradations, Structure Activity Relationship, Malignant Neoplasm, Gd-Tex, SXR, Immunomodulatory Compounds, PRR, sarcosinic acid, 11-imino-3, N-Methylglycine, Protein Digestion, Digestions, not genetically inherited, development, MT, Benign, Proteolyses, 9830004M20Rik, Digestion, BPR-2, Protein, Neoplasm, 15-dimethyl-8, 13-dinitrilo-1, Structure-Activity, BXR, 14-dipropanolato-kappaN(1), (methylamino)ethanoic acid, pheromone catabolic process, SAR, Sar, primary cancer, growth pattern, non-developmental growth, Protein Digestions, postnatal growth, Relationships, Benign Neoplasms, Cancers, malignant tumor, Malignant Neoplasms, Gd texaphyrin, sar, multicellular organismal protein catabolic process, 10-diethyl-20, Agents, 6:16, Immunomodulatory IMiDE, PAR2, PAR1, (PB-7-11-233'2'4)-bis(acetato-kappaO)(9, growth, Immunomodulatory IMiD Drugs., Neoplasiatreatment, Therapy, Malignant Neoplasm, Malignancy, Zfpn1a1, Hs.54452, ZNFN1A1, IK1, Neoplasms, RGD1562979, Benign Neoplasm, hIk-1, Benign Neoplasms, Cancers, Tumor, LYF1, Malignant, Treatments, PPP1R92, Neoplasias, IKAROS, hlk-1, Benign, Therapeutic, 5832432G11Rik, disease management, Therapies, Neoplasm, Znfn1a1, Treatment, Ikaros, Malignancies, mKIAA4227, PRO0758, LyF-1, Neoplasia, Cancer, Tumors, Malignant Neoplasms.falseDiscovery of novel potent triple IKZF1/2/3 degraders for the treatment of hematological cancersThrough subsequent investigations into structure-activity relationships (SAR) and protein degradation mechanisms, we developed a novel and highly effective candidate, MGD-22, demonstrates potent inhibition of hematological cancer growth across a broad range of models and overcame acquired resistance to IMiDs.Wed Jan 08 00:00:00 GMT 2025PXD0595729606